Showing 1011-1020 of 1211 results for "".
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- ADA and Genentech Launch Campaign to Raise Awareness and Address Inequity in Diabetes-Related Eye Diseasehttps://modernod.com/news/ada-and-genentech-launch-campaign-to-raise-awareness-and-address-inequity-in-diabetes-related-eye-disease/2481933/The American Diabetes Association (ADA) and Genentech, anchor partner of the ADA’s 'Health Equity Now' program, launched the 'Eye Pledge to Fight Diabetes.' This program encourages people with diabetes and their loved ones to get an annual eye exam, which have
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE
- Otsuka and ShapeTX Collaborate to Develop AAV Gene Therapies for Ocular Diseaseshttps://modernod.com/news/otsuka-and-shapetx-collaborate-to-develop-aav-gene-therapies-for-ocular-diseases/2481832/Otsuka Pharmaceutical and ShapeTX, a programmable medicine company using artificial intelligence (AI) and RNA to combat genetic diseases, announced a multitarget collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional t
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- ChromaDex: Nicotinamide Riboside (NR) May be a Potential Therapeutic Strategy for Glaucoma Patientshttps://modernod.com/news/chromadex-nicotinamide-rrboside-nr-may-be-a-potential-therapeutic-strategy-for-glaucoma-patients/2481733/ChromaDex announced promising findings from two independent clinical study abstracts originally presented in April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting and recently published in the peer-reviewed ARVO journal, Investigativ
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s